Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Richard_Saynor
|
| gptkbp:country |
gptkb:Switzerland
|
| gptkbp:focus |
access to healthcare
affordable medicines |
| gptkbp:founded |
1886
|
| gptkbp:founder |
gptkb:Alfred_Kern
gptkb:Edouard_Sandoz |
| gptkbp:headquarters_location |
Basel
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sandoz AG
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:listedOn |
gptkb:SIX_Swiss_Exchange
|
| gptkbp:notable_executive |
gptkb:Richard_Saynor
|
| gptkbp:notableProduct |
LSD (historically)
penicillin (historically) |
| gptkbp:numberOfEmployees |
~22,000
|
| gptkbp:operatesIn |
global
|
| gptkbp:parentCompany |
gptkb:Novartis
|
| gptkbp:products |
biosimilars
generic drugs |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:spinOff |
gptkb:Novartis
2023 |
| gptkbp:stockExchange |
gptkb:SIX_Swiss_Exchange
gptkb:SMI_MID |
| gptkbp:stockSymbol |
gptkb:SDZ
|
| gptkbp:website |
https://www.sandoz.com/
|
| gptkbp:bfsParent |
gptkb:Sandoz_(until_2023_spin-off)
|
| gptkbp:bfsLayer |
6
|